{"id":558721,"date":"2026-07-15T12:30:00","date_gmt":"2026-07-15T10:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=558721"},"modified":"2026-07-15T13:19:11","modified_gmt":"2026-07-15T11:19:11","slug":"sglt-2-i-et-glp-1-ra-amelioration-significative-des-criteres-devaluation-renaux","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/sglt-2-i-et-glp-1-ra-amelioration-significative-des-criteres-devaluation-renaux\/","title":{"rendered":"SGLT-2-i et GLP-1-RA : am\u00e9lioration significative des crit\u00e8res d&#8217;\u00e9valuation r\u00e9naux"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Environ 30 \u00e0 40 % des patients atteints de diab\u00e8te de type 2 d\u00e9veloppent une insuffisance r\u00e9nale chronique (IRC) au cours de leur maladie. Des \u00e9tudes \u00ab de r\u00e9f\u00e9rence \u00bb telles que CREDENCE, DAPA-CKD, EMPA-KIDNEY et quelques autres,<em> les inhibiteurs du SGLT-2 (transporteur 2 li\u00e9 au sodium et au glucose)<\/em>ont d\u00e9montr\u00e9 des b\u00e9n\u00e9fices av\u00e9r\u00e9s sur les crit\u00e8res d&#8217;\u00e9valuation r\u00e9naux ; l&#8217;\u00e9tude FLOW a quant \u00e0 elle permis de mettre en \u00e9vidence des effets n\u00e9phroprotecteurs significatifs<em> du GLP-1 (peptide analogue au glucagon de type 1)-RA<\/em>a \u00e9galement permis de d\u00e9montrer des effets n\u00e9phroprotecteurs significatifs chez les patients atteints de diab\u00e8te de type 2.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fsglt-2-i-et-glp-1-ra-amelioration-significative-des-criteres-devaluation-renaux%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Environ 30 \u00e0 40 % des patients atteints de diab\u00e8te de type 2 d\u00e9veloppent une insuffisance r\u00e9nale chronique (IRC) au cours de leur maladie. Des \u00e9tudes \u00ab de r\u00e9f\u00e9rence \u00bb&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fsglt-2-i-et-glp-1-ra-amelioration-significative-des-criteres-devaluation-renaux%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":558724,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Maladie r\u00e9nale chronique chez les patients atteints de diab\u00e8te de type 2 : traitement optimis\u00e9 fond\u00e9 sur des donn\u00e9es probantes","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11549,11404,11527,11531,11315,11434],"tags":[24207,12826,94719,66548,23395,12050,94726,44134,94725,20725,65614,94720,12838,94722,18589],"powerkit_post_featured":[],"class_list":["post-558721","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-endocrinologie-et-diabetologie","category-etudes","category-formation-continue","category-medecine-interne-generale","category-nephrologie-fr","tag-canagliflozine","tag-ckd-fr","tag-credence","tag-dapa-ckd-fr","tag-dapagliflozine","tag-diabete-de-type-2","tag-effets-nephroprotecteurs","tag-empagliflozine","tag-etude-flow","tag-forxiga-fr","tag-glp-1-ra-fr-2","tag-jardiance","tag-maladie-renale-chronique","tag-ozempic","tag-sglt-2-i-fr","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-08-21 20:28:31","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":558728,"slug":"sglt-2-i-e-glp-1-ra-miglioramento-significativo-degli-esiti-renali","post_title":"SGLT-2-i e GLP-1-RA: miglioramento significativo degli esiti renali","href":"https:\/\/medizinonline.com\/it\/sglt-2-i-e-glp-1-ra-miglioramento-significativo-degli-esiti-renali\/"},"pt_PT":{"locale":"pt_PT","id":558765,"slug":"sglt-2-i-e-glp-1-ra-melhoria-significativa-nos-parametros-renais","post_title":"SGLT-2-i e GLP-1-RA: melhoria significativa nos par\u00e2metros renais","href":"https:\/\/medizinonline.com\/pt-pt\/sglt-2-i-e-glp-1-ra-melhoria-significativa-nos-parametros-renais\/"},"es_ES":{"locale":"es_ES","id":558772,"slug":"inhibidores-de-sglt-2-y-agonistas-selectivos-del-glp-1-mejora-significativa-de-los-criterios-de-valoracion-renales","post_title":"Inhibidores de SGLT-2 y agonistas selectivos del GLP-1: mejora significativa de los criterios de valoraci\u00f3n renales","href":"https:\/\/medizinonline.com\/es\/inhibidores-de-sglt-2-y-agonistas-selectivos-del-glp-1-mejora-significativa-de-los-criterios-de-valoracion-renales\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/558721","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=558721"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/558721\/revisions"}],"predecessor-version":[{"id":558727,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/558721\/revisions\/558727"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/558724"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=558721"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=558721"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=558721"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=558721"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}